Phreesia vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
Phreesia logo

Phreesia

EmergingHealthcare

Patient Intake

NYSE-listed (PHR) patient intake platform digitizing check-in for 4,000+ practices at $383M revenue; pharma-funded activation programs competing with Epic and Clearwave for healthcare front-office engagement.

AI VisibilityBeta
Overall Score
C40
Category Rank
#379 of 596
AI Consensus
78%
Trend
up
Per Platform
ChatGPT
38
Perplexity
35
Gemini
44

About

Phreesia is a Raleigh, North Carolina-based patient intake and engagement platform — listed on NYSE (NYSE: PHR) — providing healthcare practices, health systems, and pharmaceutical companies with digital tools for patient registration, insurance verification, payment collection, clinical pre-screening, and patient activation. Founded in 2005 by Chaim Indig and Evan Roberts and generating $383 million in revenue in fiscal year 2025 (ending January 2025), Phreesia serves 4,000+ healthcare practices and health systems with the patient-facing digital infrastructure that replaces paper clipboards and manual front-desk registration.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#379
Category Rank
#1
78
AI Consensus
80
up
Trend
stable
38
ChatGPT
94
35
Perplexity
89
44
Gemini
94
42
Claude
92
38
Grok
98

Key Details

Category
Patient Intake
Enterprise
Tier
Emerging
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Phreesia
Patient Intake

Integrations

Only Pfizer
Phreesia is classified as company. Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.